Genflow Biosciences Plc · LSE:GENF
Genflow Biosciences — Investor Presentation (March 2026)
20 slides from Genflow Biosciences's investor presentation, March 2026
Slide 1: Corporate Overview
CORPORATE OVERVIEW March 2026 gb LSE: GENF - OTCQB: GENFF
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains express or implied information and statements that might be deemed forward-looking information and statements in respect of Genflow Biosciences. They do not constitute historical facts. Certain information and statements include financial project
Slide 3: Who We Are
WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer Healthier Life MISSION PROPRIETARY CENT SIRT6 GENE We develop gene therapies that target aging at its Centenarian SIRT6 (cent SIRT6) source—slowing or halting the process in Proprietary variant found in long-lived humans humans and dogs. tha
Slide 4: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD DR. VERA DR. ERIC VERDIN DR. MATTHEW DR. MANLIO PROF. DR. SVEN DR. MARY GORBUNOVA, PHD MD/PHD HIRSCHEY, PHD VINCIGUERRA, PHD FRANCQUE, PHD RINELLA, MD CO Director CEO & President Assistant Professor Principle Investigator NASH Expert NASH Expert Rochester Aging Buck Institu
Slide 5: Management
MANAGEMENT GAD BERDUGO DR ERIC LEIRE MD MBA Chairperson Founder & CEO • Managing Partner of Explorium Capital with 35+ years of • MD and MBA, Eric has been involved in leadership across global biotech business & corporate biotech for over 30 years development, venture management and U.S. capital mar
Slide 6: Gene Regulation in Aging
GENE REGULATION IN AGING Aging is a function of overworked epigenetic regulator genes unable to respond to cellular DNA damage GENOME MANY GENES REGULATE AGING. INSTABILITY OUR FOCUS IS THE CENTENARIAN SIRT6 (cent ALTERED INTRA CELLULAR TELOMERE SIRT6) GENE COMMUNICATION ATTRITION Aging is driven by
Slide 7: Why SIRT6
WHY SIRT6 Master regulator of DNA repair, metabolism, inflammation, aging Centenarian SIRT6 variant with enhanced activity Broad relevance across liver, retina, systemic aging SIRT6: REPAIRING DNA Lifespan 5 different LIFESPAN DSB repair amino acids between SIRT6 SIRT6 activity protein of mouse and
Slide 8: SIRT6cent Edge: Centenarian Genetics Validated Benefit
SIRT6CENT EDGE:CENTENARIAN GENETICS VALIDATED BENEFIT SIRT6c gene Sirtuins are a family of highly conserved signaling proteins involved in metabolic regulation and implicated in influencing cellular processes incl. aging, Sirtuin 6 (SIRT6 ) is a stress responsive NAD+- dependent histone deacetylase
Slide 9: Development Pipeline
DEVELOPMENT PIPELINE Centenarian SIRT6 Gene Therapy Platform • Priority Programs Completed Ongoing Planned PROGRAM PRE-CLINICAL IND-ENABLING PHASE I/II PHASE II/III Anti-Aging Dogs GF-1004 AAV8 / Naked DNA • cent SIRT6 ✓ ✓ ● ONGOING Clinical POC — Planned Completed Completed Readout Q1 2026 Veterina
Slide 10: Rationale for SIRT6 Use to Extend Lifespan
RATIONALE FOR SIRT6 USE TO EXTEND LIFESPAN SIRT6 transgenic mice SIRT6 knockout(KO) SIRT6 Overexpression(OE) Cell. 2006 Jan 27;124(2):315-29. LSE: GENF - OTCQB: GENFF 10
Slide 11: Rationale for SIRT6 Use in Aged Dogs
RATIONALE FOR SIRT6 USE IN AGED DOGS SIRT6 OE in aged cells reverses epigenetic age (DNA mAge) a ✱ b ✱ 55 DNA methylation age DNA methylation age 50 50 45 40 40 35 30 30 Control SIRT6 T6 ol tr R on SI C LSE: GENF - OTCQB: GENFF 11
Slide 12: Rationale for SIRT6 Use in Sarcopenia
RATIONALE FOR SIRT6 USE IN SARCOPENIA Genflow SIRT6 study conducted with Rochester University, NY Frailty Test in Mice Centenarian SIRT6 demonstrates statistically significant improvement 18-month-old male mice LSE: GENF - OTCQB: GENFF 12
Slide 13: Aged Dogs Comparative Trial (SLAB)
AGED DOGS COMPARATIVE TRIAL (SLAB) Proof-of-Concept: in-vivo randomized blinded naked DNA gene therapy in aged beagles TRIAL DESIGN KEY ENDPOINTS (Q2 2026) CRO Syngene (GLP-certified facility) Pan-mammalian methylation clock Epigenetic age (GrimAge) Animals 26 aged Beagles (24 + 2 reserve), age > 10
Slide 14: Naked DNA Delivery for Dogs
NAKED DNA DELIVERY FOR DOGS Naked DNA in vivo delivery in small mammals like dogs holds several advantages: Safety and Simplicity: Naked DNA lacks viral components, reducing the risk of immune responses and integration-related mutagenesis, making it safer than viral vectors. Cost-Effectiveness: Unli
Slide 15: Glaucoma RGC Neuroprotection: The Race Is On
GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON Significant market opportunity 80M people worldwide with glaucoma Leading cause of irreversible blindness The Problem: unmet need for neuroprotection Current treatments only lower IOP They don't protect retinal
Slide 16: Partnering with LNP Providers
16 PARTNERING WITH LNP PROVIDERS Paradigm shift to retinal protection • Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma / optic neuropathy models • Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal IVT delivery is now tractable • Op
Slide 17: Advanced MASH Program
ADVANCED MASH PROGRAM Affects est. 35 million people globally Increasing prevalence Significant unmet medical need for Advanced MASH Leading cause of chronic liver disease and liver transplant Clear regulatory accelerated development pathway Multi-pathway disease modification Liver-targeted mRNA/LNP
Slide 18: 2026 Key Milestones
2026 KEY MILESTONES Large & Expanding Market Growing IP Portfolio Advanced MASH: High unmet needs, rising prevalence 2 proprietary patent families: cent SIRT6 & gene delivery Gateway to broader anti-aging indication Both patent families entering National Phase (PCT) Strategic value Ophthalmology: 80
Slide 19: Value Inflection Timeline
VALUE INFLECTION TIMELINE Upcoming catalysts expected to drive significant value creation in 2026–27 Q1 2026 2026–27 Aged Dog Trial Interim MASH IND-Enabling → IND- Readout Ready Pan-mammalian epigenetic age clock 18 months to first-in-human (GrimAge) + sarcopenia endpoints in 36-patient Phase I/II
Slide 20: Thank You / Contacts
THANK YOU Contacts CEO, GENFLOW BIOSCIENCES Dr. Eric Leire: +32 477 495 881 HARBOR ACCESS INVESTOR RELATIONS Jonathan Paterson : +1 475 477 9401 GENFLOW BIOSCIENCES SRL Biopark Gosselies Clement Ader 10 6041 Gosselies, Belgium GENFLOW BIOSCIENCES Plc 6 Heddon Street London W1B 4BT UK GENFLOW BIOSCIE
Genflow Biosciences — Investor Presentation (March 2026) on 6ix